Update: Relay Medical Joint Spectroscopic and Biosensor System for Point-of-Care Testing Patent Granted in China
(firmenpresse) -
January 7, 2019 - Relay Medical Corp. (Relay or the Company) (CSE: RELA, OTC: RYMDF, Frankfurt: EIY2) is pleased to announce an update to September 11th news release regarding the approval for grant of Chinese Patent Application No. 201580025752.6. The company has been informed that the patent has been officially granted by the Chinese patent authority as patent number CN106716137B with an expiry date of May 20, 2035. This new patent continues to expand the broad reach of Relays intellectual property portfolio for its HemoPalm Analysis Platform in a rapidly advancing market for healthcare technologies.
About Relay Medical Corp.
Relay Medical is an evolving Integrated Medtech Accelerator headquartered in Toronto, Canada, advancing multiple opportunities for commercialization within a resource efficient infrastructure. Relay is also actively dedicated to scouting and reviewing strategic acquisitions complimentary to current infrastructure assets and intends to grow as a leading engine for MedTech innovation in the health technologies marketplace.
Website: www.relaymedical.com
Contact:
W. Clark Kent
President
Relay Medical Corp.
Office. 647-872-9982 ext. 2
TF. 1-844-247-6633 ext. 2
investor.relations(at)relaymedical.com
Contact:
Office: 647-872-9982
Toll-free/Fax: 1-844-247-6633
Email: info(at)relaymedical.com
Suite 1600-401 Bay St.
Toronto, Ontario M5H 2Y4
Bernhard Langer
EU Investor Relations
Office. +49 (0) 177 774 2314
Email: blanger(at)relaymedical.com
Forward-looking Information Cautionary Statement
Except for statements of historic fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Companys control. There are no assurances that the commercialization plans for the HemoPalm product described in this news release will come into effect on the terms or time frame described herein. The Company undertakes no obligation to update forward-looking information if circumstances or management''s estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Companys filings with Canadian securities regulators, which filings are available at www.sedar.com
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
" alt="Nicola Mining Announces Mineral Claim Acquisitions and Expansion of New Craigmont Land Package">
" alt="Blue Lagoon enters into definitive Agreement with Quebec based Mag One Operations to form Joint Venture">
Datum: 07.01.2020 - 16:01 Uhr
Sprache: Deutsch
News-ID 1555089
Anzahl Zeichen: 3368
contact information:
Contact person:
Town:
Wien
Phone:
Kategorie:
Business News
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 1090 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Update: Relay Medical Joint Spectroscopic and Biosensor System for Point-of-Care Testing Patent Granted in China
"
steht unter der journalistisch-redaktionellen Verantwortung von
Relay Medical Corp. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
